This article is more than 5 years old. Information may no longer be current.
Study reveals different remission intervals for two anti-VEGFs
WAILEA, Hawaii — Preliminary data reported here support the clinical impression that there is a difference between bevacizumab and ranibizumab in short-term biologic effect and in durability of activity, leading to differences in remission intervals in patients treated for neovascular age-related macular degeneration.
In a retrospective analysis of 52 patients treated with Lucentis (ranibizumab, Genentech) and 68 patients treated with Avastin (bevacizumab, Genentech), Tom S. Chang, MD, and colleagues found mean remission times to be 6.6 months for bevacizumab and 3.8 months for ranibizumab. Dr. Chang presented the results at the American Society of Retina Specialists annual meeting.
Qualitative analysis by optical coherence tomography and clinical parameters were used to determine a recurrence of choroidal neovascular activity.
"In our series, anybody who had any fluid at any time was re-treated," Dr. Chang said.
The researchers said the advantage of ranibizumab is its short-term biologic effect and the advantage of bevacizumab is its durability of activity.